All News

It has been six years since a French biotech company made a stock market debut – and now two, BioAlliance and ExonHit, are doing so. Is the European market reawakening?

The pace of forming academic spin-out companies picked up in the US in 2004 after a two-year slump, according to a survey released today.

After the initial hype, the long haul through clinical development and the inevitable pitfalls, gene therapy is on the verge of becoming a commercial reality in Europe - ahead of the US.

Not all nanotechnology is hype. Carbon nanotubes are already inside a product near you.

The Cambridge-based company a.gain medical says it has invented the world's first urethral sensor for women – and is looking for further investment.

A team of European researchers is applying a technology used to measure airflow over aircraft wings to improve human heart implants.

Britain's privatised defence lab ties up with 7 universities, in a strategy to do more with fewer partners.

UK-based AMDG's monitor for early detection of heart conditions particularly associated with diabetics is already selling in Germany. Now the company is now looking for support to enter into the US market.

Tracking 15 key technologies, fraud in nanotechnology - and other insights into R&D management

A spin-out from Sheffield that uses stem cells to help with conventional drug discovery is looking for investment to continue pre-clinical research on therapeutic applications and business development activities.

Nuala Moran takes a behind-the-scenes look at the strategies involved in Europe's biggest patent victory in years.

For her latest fortnightly funding column, Mary Lisbeth D'Amico set out to find European seed funders. That was as easy as finding a needle in a haystack.

A spin-out from Sheffield University and Northwick Park Institute for Medical Research says it has created a compound using carbon monoxide that could save lives by helping with organ transplants.

When Google hired Kai-fu Lee from Microsoft to set up the internet company's new R&D centre in Beijing in July, it set off a legal battle that highlights how much is at stake in the rush to cash in on the country's booming economy and vast scientific labour force.

British drug-delivery company Phoqus blamed "unfavourable market" conditions for meeting only its minimum target of £10 million in its initial public offering.